INMB
INmune Bio Inc.
Company Overview
| Mkt Cap | $41.21M | Price | $1.40 |
| Volume | 217.55K | Change | -2.10% |
| P/E Ratio | -0.9 | Open | $1.42 |
| Revenue | $50.0K | Prev Close | $1.43 |
| Net Income | $-45.9M | 52W Range | $1.09 - $11.64 |
| Div Yield | N/A | Target | $7.00 |
| Overall | 50 | Value | 60 |
| Quality | 47 | Technical | 45 |
No chart data available
About INmune Bio Inc.
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Latest News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Inmune Bio (INMB) and Joint (JYNT)
Inmune Bio Advances CORDStrom Amid Funding Pressures
INmune Bio Expands Cord Tissue License for CORDStrom Platform
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | INMB | $1.40 | -2.1% | 217.55K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |